Lipid Profile, Lipid-lowering Medications, and Intracerebral Hemorrhage After tPA in Get With The Guidelines–Stroke

Background and Purpose— Symptomatic intracerebral hemorrhage (sICH) after tissue plasminogen activator for acute ischemic stroke is associated with poor outcome. There are conflicting data on sICH risk related to lipid levels and use of lipid-lowering medications. We evaluated whether there are associations between lipid levels, lipid-lowering medications, and sICH in Get With the Guidelines-Stroke. Methods— We identified acute ischemic stroke patients in the Get With the Guidelines-Stroke data set who were treated with IV tissue plasminogen activator between April 2003 and September 2009 and had complete data on lipid profiles and complications. Potential predictors of sICH were tested in univariate and multivariate analysis. Results— The analysis included 22 216 IV tissue plasminogen activator–treated acute ischemic stroke patients. Overall, 1104 (4.97%) experienced sICH (National Institute of Neurological Disorders and Stroke definition). In univariate analysis, patients with sICH were more often taking antihypertensive, lipid-lowering, and diabetes mellitus medications. There was no relationship between low density lipoprotein or total cholesterol and sICH in univariate analysis. However, the risk of sICH increased with higher high density lipoprotein, 6.1% in Q4 versus 4.7% in Q1, P=0.0013; and lower triglyceride levels, 5.9% in Q1 versus 4.2% in Q4, P<0.0001. In multivariable models, although the high density lipoprotein and triglyceride levels were modestly associated with sICH, low density lipoprotein and total cholesterol were not. Lipid-lowering medications were not independently associated with sICH. Conclusions— We found that low density lipoprotein and total cholesterol levels are not associated with risk of sICH after tissue plasminogen activator, although higher high density lipoprotein and lower triglyceride levels were modest risk factors. Lipid-lowering medications are not associated with risk of sICH.

[1]  D. Leys,et al.  Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia , 2012, Neurology.

[2]  Gary A. Ford,et al.  Predicting the Risk of Symptomatic Intracerebral Hemorrhage in Ischemic Stroke Treated With Intravenous Alteplase: Safe Implementation of Treatments in Stroke (SITS) Symptomatic Intracerebral Hemorrhage Risk Score , 2012, Stroke.

[3]  M. Kaste,et al.  Symptomatic intracranial hemorrhage after stroke thrombolysis: The SEDAN Score , 2012, Annals of neurology.

[4]  Eric E. Smith,et al.  Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. , 2012, American heart journal.

[5]  A. Hofman,et al.  Serum Lipid Levels and the Risk of Intracerebral Hemorrhage: The Rotterdam Study , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[6]  Eric E. Smith,et al.  Statins and Intracerebral Hemorrhage: Collaborative Systematic Review and Meta-Analysis , 2011, Circulation.

[7]  R. Bordet,et al.  IV thrombolysis and statins , 2011, Neurology.

[8]  M. Kaste,et al.  Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis , 2011, Neurology.

[9]  Adrian F Hernandez,et al.  Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes , 2011, Circulation.

[10]  R. Delgado-Mederos,et al.  Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case–control study and a meta-analysis , 2011, Journal of Neurology.

[11]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[12]  J. De Keyser,et al.  Statin Use and Functional Outcome after Tissue Plasminogen Activator Treatment in Acute Ischaemic Stroke , 2010, Cerebrovascular Diseases.

[13]  G. Duckwiler,et al.  Impact of Hyperlipidemia and Statins on Ischemic Stroke Outcomes after Intra-Arterial Fibrinolysis and Percutaneous Mechanical Embolectomy , 2009, Cerebrovascular Diseases.

[14]  G. Schroth,et al.  Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. , 2009, Stroke.

[15]  W. Ryu,et al.  Low level of low-density lipoprotein cholesterol increases hemorrhagic transformation in large artery atherothrombosis but not in cardioembolism. , 2009, Stroke.

[16]  M. Vermeulen,et al.  HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDY , 2009, Neurology.

[17]  D. Tanné,et al.  A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. , 2008, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[18]  G Schlaug,et al.  The HAT Score , 2008, Neurology.

[19]  M. Hennerici,et al.  Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study , 2008, Neurology.

[20]  G. Luijckx,et al.  Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke , 2008, Journal of Neurology.

[21]  N. Salamon,et al.  Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis , 2007, Neurology.

[22]  C. Molina,et al.  Prior Statin Use May Be Associated With Improved Stroke Outcome After Tissue Plasminogen Activator , 2007, Stroke.

[23]  Jun Ma,et al.  National Trends in Statin Use by Coronary Heart Disease Risk Category , 2005, PLoS medicine.

[24]  Lynn A Smaha,et al.  The American Heart Association Get With The Guidelines program. , 2004, American heart journal.

[25]  J. Mehta,et al.  Anti-thrombotic Effects of Atorvastatin-An Effect Unrelated to Lipid Lowering , 2002, Journal of cardiovascular pharmacology and therapeutics.

[26]  Andrew M. Demchuk,et al.  Markers of Increased Risk of Intracerebral Hemorrhage After Intravenous Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke in Clinical Practice: The Multicenter rt-PA Acute Stroke Survey , 2002, Circulation.

[27]  D. Albanes,et al.  Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. , 1999, Stroke.

[28]  G. Lowe,et al.  Effects of lipids and lipoproteins on thrombosis and rheology. , 1998, Atherosclerosis.

[29]  P. Allhoff,et al.  The Honolulu Heart Program , 1991 .

[30]  D. Reed,et al.  Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. , 1989, Stroke.

[31]  D. Jacobs,et al.  Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.